Summary
Maps companion diagnostic co-development requirements, FDA PMA/510(k) precedents, and diagnostic partnering strategies for biomarker-driven programs.
Detailed Description
The Companion Diagnostic Strategy Pack addresses the regulatory and operational complexities of co-developing a companion diagnostic (CDx) alongside a therapeutic product. It compiles FDA guidance on drug-diagnostic co-development, PMA and 510(k) approval precedents for oncology diagnostics, and practical strategies for diagnostic partner selection and timeline alignment.
The pack maps the parallel regulatory pathways for your drug and diagnostic, identifying critical synchronization points and potential timeline risks. It analyzes precedent CDx approvals to benchmark regulatory timelines, clinical validation study designs, and bridging study requirements.
Deliverables include a CDx co-development strategy and timeline, a diagnostic partner evaluation framework, and a regulatory pathway analysis comparing PMA and 510(k) routes for your candidate diagnostic with precedent-based timeline estimates.
Evidence Sources
| Source | Type | Description | Refresh |
|---|---|---|---|
| FDA CDx Guidance | REGULATORY | FDA guidance on drug-diagnostic co-development, companion diagnostic labeling, and review procedures | Monthly |
| Diagnostic Approval Database | REGULATORY | FDA PMA and 510(k) approval database for companion and complementary diagnostics with review timelines | Monthly |
| CDx Development Precedents | CURATED | Curated database of CDx co-development programs with partnering strategies, timelines, and outcomes | Quarterly |
Regulatory Mapping
Principles for Codevelopment of an In Vitro Companion Diagnostic Device with a Therapeutic Product
In Vitro Companion Diagnostic Devices: Guidance for Industry and Food and Drug Administration Staff
Developing and Labeling In Vitro Companion Diagnostic Devices for a Specific Group or Class of Oncology Therapeutic Products
Agent Transparency
When you run this pack, your request is processed by a pipeline of specialized AI agents. Each agent operates with a defined confidence threshold and is auditable end-to-end.
Evidence Retriever
brew-retriever-v3
Queries curated sources for relevant evidence objects. Searches across regulatory databases, clinical registries, and scientific literature to surface the most pertinent references for the pack domain.
Domain Analyzer
brew-domain-analyst-v2
Applies domain-specific reasoning and regulatory mapping. Interprets evidence in the context of FDA, ICH, and EMA frameworks and tags each finding with the relevant guidance references.
Evidence Synthesizer
brew-synthesizer-v2
Synthesizes findings into structured output. Combines retrieved evidence and domain analysis into a cohesive narrative with quantitative summaries, comparative tables, and actionable recommendations.
Output Validator
brew-validator-v1
Validates citations, checks confidence thresholds, and ensures all referenced sources are accessible and correctly attributed. Flags any claims that fall below the confidence floor.
Sample Outputs
CDx Co-Development Strategy
PDFEnd-to-end co-development strategy with synchronized drug and diagnostic timelines
Diagnostic Partner Evaluation
XLSXFramework for evaluating and selecting diagnostic development partners with scoring criteria
Regulatory Pathway Analysis
PDFComparative analysis of PMA vs 510(k) pathways with precedent-based timeline estimates
Deliverables included
- CDx co-development strategy and timeline
- Diagnostic partner evaluation framework
- Regulatory pathway comparison (PMA vs 510(k))
- Clinical validation study design recommendations
- Bridging study requirements analysis
Related Disease & Biomarker Mappings
| Therapeutic Area | Disease Family | Key Biomarkers | Relevance |
|---|---|---|---|
| Precision Medicine | Companion Diagnostics | NGS Panel CoverageIHC MarkersLiquid Biopsy ctDNA | Primary |
| Immuno-Oncology | Immune Checkpoint | PD-L1 TPS/CPSTMBMSI-H | Primary |
| Solid Tumors | Targeted Therapy | EGFRALKROS1NTRK | Secondary |
Related Packs in Biomarker & Translational
Biomarker Validation Pack
From candidate biomarker to qualified decision tool
PK/PD Modeling Intelligence Pack
Model-informed drug development backed by precedent
Target Validation Evidence Pack
Validate your target with multi-source evidence synthesis
Version History
Current release — expanded evidence sources, improved citation accuracy, and added new regulatory cross-references.
Beta release — validated with domain SMEs. Added sample output previews and refined confidence scoring.
Initial draft — core evidence retrieval pipeline and output schema established.
Need a Custom Evidence Pack?
Our enterprise team can build bespoke evidence packs tailored to your therapeutic area, regulatory strategy, or internal decision framework. Custom packs include dedicated evidence source curation, domain-specific agent tuning, and priority SLA support.
Enterprise packs are available for organizations on the BrewBio Pro or Enterprise plan.